Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:affiliatedWith |
antipsychotic medication
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:United_States
|
| gptkbp:ATCCode |
N05AX16
|
| gptkbp:CASNumber |
1620918-26-9
|
| gptkbp:developedBy |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:hasMolecularFormula |
C25H27N3O2S
|
| https://www.w3.org/2000/01/rdf-schema#label |
D08075
|
| gptkbp:marketedAs |
gptkb:Otsuka_Pharmaceutical
gptkb:Lundbeck |
| gptkbp:mechanismOfAction |
antagonist at serotonin 5-HT2A receptors
partial agonist at dopamine D2 receptors partial agonist at serotonin 5-HT1A receptors |
| gptkbp:molecularWeight |
433.57 g/mol
|
| gptkbp:PubChem_CID |
gptkb:DB12010
49806724 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:Brexpiprazole
|
| gptkbp:usedFor |
gptkb:major_depressive_disorder
schizophrenia |
| gptkbp:bfsParent |
gptkb:Heroin
|
| gptkbp:bfsLayer |
6
|